Indaptus Therapeutics Inc
Change company Symbol lookup
Select an option...
INDP Indaptus Therapeutics Inc
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc
LZM Lifezone Metals Ltd
LMRMF Lomiko Metals Inc
SOXL Direxion Daily Semiconductor Bull 3X Shares
OXSQ Oxford Square Capital Corp
BAER Bridger Aerospace Group Holdings Inc
CMRA Comera Life Sciences Holdings Inc

Health Care : Biotechnology |
Company profile

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

Day's Change
-0.21 (-7.75%)
B/A Size
Day's High
Day's Low
(Below Average)

Today's volume of 26,810 shares is on pace to be lower than INDP's 10-day average volume of 40,136 shares.


PacWest sparks regional-bank rally after unveiling plan to sell loans worth $2.6 billion

2:09 pm ET May 22, 2023 (MarketWatch)

By Ciara Linnane

Tone further boosted as Hovde initiates coverage of Zions Bancorp with a buy rating

PacWest Bancorp's stock jumped 21% Monday after the bank announced the sale of a portfolio of 74 real-estate-construction loans with a principal balance of about $2.6 billion as it moves to refocus on its core community-banking business.

The move sparked a broader rally in beaten-down regional-bank stocks, which have been volatile since the March collapse of Silicon Valley Bank and the takeover of First Republic Bank by JPMorgan Chase & Co. in early May.

There was further support for the sector from Hovde Group, which initiated coverage of Zions Bancorp with a bullish outperform rating, the equivalent of buy.

PacWest (PACW) said it is selling the loans to a unit of real-estate-investment company Kennedy Wilson Holdings.

"Kennedy Wilson or its designees will also assume all remaining future funding obligations under the acquired loans of approximately $2.7 billion," PacWest said in a regulatory filing.

The bank has also agreed to sell an additional six real-estate-construction loans with a principal balance of about $363 million to Kennedy Wilson.

The sale of the loans is subject to Kennedy Wilson's satisfactory due diligence. The company will place $20 million into a third-party escrow account that will be refundable.

The deal is expected to close in several tranches in the second and third quarters. "There can be no assurance that the transaction will be completed in part or at all," said the filing.

See also: FDIC set to levy big banks to pay for $15.8 billion bailout of Silicon Valley, Signature Banks

PacWest shares are down 73% in the year to date, caught up in the turmoil created by bank failures. The Los Angeles, Calif.-based bank said it lost 9.5% of its deposits during the week ending May 5 amid market volatility following JPMorgan's (JPM) rescue of First Republic Bank.

See:Here's why people are still worried about regional banks and commercial real estate

Also:Senators grill SVB, Signature Bank CEOs for putting profits ahead of shareholders and depositors in collapse

Meanwhile, Hovde Group said that "misplaced fears" are behind the deeply discounted valuation of Zions and that investors are overlooking its healthy profitability.

"Operationally, [Zions] looks to be firing on all cylinders, and we believe the banking market dislocation offers a very opportunistic entry point in a quality franchise," analyst Ben Gerlinger wrote in a note to clients.

Even with his conservative estimates modeling near-term deposit runoff, slower growth, higher loan-loss provisions and some concerns around office commercial real estate, "we feel very comfortable recommending the stock given the deeply discounted share price," he wrote.

Hovde assigned Zions (ZION) a $40 price target that's about 44% above its current price.

"Fundamentally, we believe the market is incorrectly pricing in a draconiandeposit environment and overlooks the looming rapid capital build; supported by earnings and the short duration bond book," said Gerlinger.

Zion's stock was up 6% in Monday afternoon trading.

Other regional banks were also higher. Western Alliance Bancorp. (WAL) was up 7% and KeyCorp (KEY) was up 3.3%. Comerica Inc. (CMA) rose 3%.

The KBW Bank exchange-traded fund was up 1.4% and the SPDR S&P Regional Banking ETF (KRE) was up 2.7%.

The S&P 500 has gained 9% in the year to date.

-Ciara Linnane

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 22, 2023 14:09 ET (18:09 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.